KellieJNazemiMD

Pediatric Hematology & Oncology • Portland, OR

Assistant Professor, Pediatrics, Oregon Health and Science University School of Medicine

Join to view full profile

Dr. Nazemi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nazemi's full profile

Already have an account?

Office
3181 Sw Sam Jackson Park Rd
Cdrc-P
Portland, OR 97239
Phone+1 503-494-1543

Fax+1 503-494-0714

Education & Training

Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2003 - 2006
Old Dominion UniversityResidency, Pediatrics, 2000 - 2003
Texas Tech University Health Sciences Center School of MedicineClass of 2000

Certifications & Licensure

OR State Medical License 2006 - 2025
MA State Medical License 2003 - 2008
VA State Medical License 2001 - 2004

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
ACTIVE_NOT_RECRUITING
Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas Start of enrollment: 2009 Jun 01
Completed
Phase 2
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) Start of enrollment: 2011 Sep 01
Terminated
Phase 2
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor Start of enrollment: 2011 Aug 01
Completed
Phase 2
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Start of enrollment: 2012 Jun 27
COMPLETED
PHASE2
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children Start of enrollment: 2012 Dec 13
COMPLETED
PHASE2
Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas Start of enrollment: 2014 Apr 29
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma Start of enrollment: 2017 Apr 04
Terminated
Early Phase 1
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas Start of enrollment: 2019 Apr 03
RECRUITING
PHASE1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients.
Mary Jane Lim-Fat, Jennifer A Cotter, Mehdi Touat, Jayne Vogelzang, Cecilia Sousa
Neuro-Oncology. 2024-12-05
11 citations
Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics.
Kee Kiat Yeo, Sanda Alexandrescu, Jennifer A Cotter, Jayne Vogelzang, Varun Bhave
Neuro-Oncology. 2023-01-05
9 citations
Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion.
Clare Keddy, Tanaya Neff, Jianya Huan, Joshua P. Nickerson, Catherine Z. Beach
Cold Spring Harbor Molecular Case Studies. 2021-10-01